Support from Vinnova

More support for Alertix’ acclaimed research. This time from Sweden’s Innovation Agency Vinnova.

Alertix plans to broaden and deepen its clinical documentation to verify initial results from smaller studies. Alertix now receives 300.000 SEK from Sweden's Innovation Agency Vinnova (programme Innovative Startups 1) to conduct a clinical verification study of its veterinary diagnostic biomarker for tumor diseases in dogs.

Alertix has received the innovation award Skapa in Kalmar county and will participate as finalist in the national Skapa award ceremony in Stockholm on the 14th of November.

Alertix Canine

Assay for early detection, monitoring and screening of tumor diseases in dogs. The assay is available to veterinary clinics and laboratories in Sweden and Scandinavia.

Alertix Feline

Assay for early detection, monitoring and screening of tumor diseases in cats. The assay is under development.

Alertix Equine

Assay for early detection, monitoring and screening of tumor diseases in horses. The assay is under development.

Under development

About cancer in companion animals

Did you know that our companion animals are afflicted by cancer as often as humans? Dogs and cats share not only our living environment but also our lifestyle. Because of this they are exposed to the same risk factors for cancer. Veterinary care is getting better and better at treating cancer in companion animals. But the crucial factor of success is that the disease is detected in time.

News

TK1 in cats

A recently published scientific paper by researchers associated with Alertix displays TK1 in cat serum to be significantly higher compared to healthy cats and compared to cats with inflammatory diseases. These results suggest that serum TK1 may be a promising biomarker for the diagnosis and monitoring of malignant diseases and for the differential diagnosis of certain inflammatory diseases.

New Board Member

M.Sc. Göran Beijer was elected as a new board member of Alertix at an extraordinary general meeting on the 17th of December 2019.

Support from Vinnova

More support for Alertix’ acclaimed research. This time from Sweden’s Innovation Agency Vinnova.

More news